Editorial
EV-based EGFR genotyping in bronchoalveolar lavage fluid—a step forward from blood?
Translational Lung Cancer Research
2020;
9
(3)
:427-429
.
(29 June 2020)
Ideal prognostic model in lung squamous cell carcinoma
Translational Lung Cancer Research
2020;
9
(3)
:430-431
.
(29 June 2020)
Dual-energy computed tomography for pre-surgical identification of adenocarcinoma subtypes
Translational Lung Cancer Research
2020;
9
(3)
:432-433
.
(29 June 2020)
Sleeve lobectomy and pneumonectomy: can they really be properly compared?
Translational Lung Cancer Research
2020;
9
(3)
:434-437
.
(29 June 2020)
Does the gut microbiota play a key role in PD-1/PD-L1 blockade therapy?
Translational Lung Cancer Research
2020;
9
(3)
:438-440
.
(29 June 2020)
Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation
Translational Lung Cancer Research
2020;
9
(3)
:441-445
.
(29 June 2020)
Original Article
Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis
Translational Lung Cancer Research
2020;
9
(3)
:446-458
.
(29 June 2020)
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
Translational Lung Cancer Research
2020;
9
(3)
:459-470
.
(29 June 2020)
EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
Translational Lung Cancer Research
2020;
9
(3)
:471-483
.
(29 June 2020)
Determining the invasiveness of pure ground-glass nodules using dual-energy spectral computed tomography
Translational Lung Cancer Research
2020;
9
(3)
:484-495
.
(29 June 2020)
The prevalence and prognostic significance of estrogen receptor beta expression in non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:496-506
.
(29 June 2020)
Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board
Translational Lung Cancer Research
2020;
9
(3)
:507-514
.
(29 June 2020)
18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:515-521
.
(29 June 2020)
Role of chest radiographs in early lung cancer detection
Translational Lung Cancer Research
2020;
9
(3)
:522-531
.
(29 June 2020)
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
Translational Lung Cancer Research
2020;
9
(3)
:532-540
.
(29 June 2020)
Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy
Translational Lung Cancer Research
2020;
9
(3)
:541-548
.
(29 June 2020)
Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features
Translational Lung Cancer Research
2020;
9
(3)
:549-562
.
(29 June 2020)
18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma
Translational Lung Cancer Research
2020;
9
(3)
:563-574
.
(29 June 2020)
Novel genetic variants in genes of the Fc gamma receptor-mediated phagocytosis pathway predict non-small cell lung cancer survival
Translational Lung Cancer Research
2020;
9
(3)
:575-586
.
(29 June 2020)
Large nest micropapillary pattern of lung adenocarcinoma has poorer prognosis than typical floret pattern: analysis of 1,062 resected tumors
Translational Lung Cancer Research
2020;
9
(3)
:587-602
.
(29 June 2020)
Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis
Translational Lung Cancer Research
2020;
9
(3)
:603-616
.
(29 June 2020)
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
Translational Lung Cancer Research
2020;
9
(3)
:617-628
.
(29 June 2020)
Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma
Translational Lung Cancer Research
2020;
9
(3)
:629-638
.
(29 June 2020)
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
Translational Lung Cancer Research
2020;
9
(3)
:639-645
.
(29 June 2020)
The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility
Translational Lung Cancer Research
2020;
9
(3)
:646-658
.
(29 June 2020)
Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes
Translational Lung Cancer Research
2020;
9
(3)
:659-669
.
(29 June 2020)
Integrated analysis of optical mapping and whole-genome sequencing reveals intratumoral genetic heterogeneity in metastatic lung squamous cell carcinoma
Translational Lung Cancer Research
2020;
9
(3)
:670-681
.
(29 June 2020)
Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling
Translational Lung Cancer Research
2020;
9
(3)
:682-692
.
(29 June 2020)
Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:693-704
.
(29 June 2020)
Bioengineered carina reconstruction using In-Vivo Bioreactor technique in human: proof of concept study
Translational Lung Cancer Research
2020;
9
(3)
:705-712
.
(29 June 2020)
The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:713-721
.
(29 June 2020)
Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:722-730
.
(29 June 2020)
PRRX1 isoform PRRX1A regulates the stemness phenotype and epithelial-mesenchymal transition (EMT) of cancer stem-like cells (CSCs) derived from non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2020;
9
(3)
:731-744
.
(29 June 2020)
The effect of combining Endostar with radiotherapy on blood vessels, tumor-associated macrophages, and T cells in brain metastases of Lewis lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:745-760
.
(29 June 2020)
Brief Report
Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:761-767
.
(29 June 2020)
Review Article
Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure
Translational Lung Cancer Research
2020;
9
(3)
:768-786
.
(29 June 2020)
Case Report
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report
Translational Lung Cancer Research
2020;
9
(3)
:787-792
.
(29 June 2020)
Clinical impact of the lung tissue transcriptome in a teenager with multifocal invasive mucinous adenocarcinoma—a case report
Translational Lung Cancer Research
2020;
9
(3)
:793-802
.
(29 June 2020)
Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report
Translational Lung Cancer Research
2020;
9
(3)
:803-806
.
(29 June 2020)
Letter to the Editor
cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
Translational Lung Cancer Research
2020;
9
(3)
:807-810
.
(29 June 2020)
Editorial Commentary
The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
Translational Lung Cancer Research
2020;
9
(3)
:811-815
.
(29 June 2020)
Screening-detected pure ground-glass opacities: malignant potential beyond conventional belief?
Translational Lung Cancer Research
2020;
9
(3)
:816-818
.
(29 June 2020)
First-line immune-chemotherapy combination for squamous NSCLC is already a reality
Translational Lung Cancer Research
2020;
9
(3)
:819-823
.
(29 June 2020)
Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2020;
9
(3)
:824-827
.
(29 June 2020)
Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:828-832
.
(29 June 2020)
A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
Translational Lung Cancer Research
2020;
9
(3)
:833-836
.
(29 June 2020)
Editorial on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting1
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting
Translational Lung Cancer Research
2020;
9
(3)
:837-838
.
(29 June 2020)
Review Article on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting1
Controversies and challenges in the histologic subtyping of lung adenocarcinoma
Translational Lung Cancer Research
2020;
9
(3)
:839-846
.
(29 June 2020)
Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective
Translational Lung Cancer Research
2020;
9
(3)
:847-859
.
(29 June 2020)
Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis
Translational Lung Cancer Research
2020;
9
(3)
:860-878
.
(29 June 2020)
Lung cancer biomarker tests: the history and perspective in Japan
Translational Lung Cancer Research
2020;
9
(3)
:879-886
.
(29 June 2020)
Lung cancer biomarker testing: perspective from Europe
Translational Lung Cancer Research
2020;
9
(3)
:887-897
.
(29 June 2020)
Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer
Translational Lung Cancer Research
2020;
9
(3)
:898-905
.
(29 June 2020)
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies
Translational Lung Cancer Research
2020;
9
(3)
:906-916
.
(29 June 2020)
Update on the pathologic diagnosis of malignant mesothelioma
Translational Lung Cancer Research
2020;
9
(3)
:917-923
.
(29 June 2020)
Clinical significance of histologic subtyping of malignant pleural mesothelioma
Translational Lung Cancer Research
2020;
9
(3)
:924-933
.
(29 June 2020)
Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
Translational Lung Cancer Research
2020;
9
(3)
:934-943
.
(29 June 2020)
Erratum
Erratum to Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
Translational Lung Cancer Research
2020;
9
(3)
:944
.
(29 June 2020)
Disclosure:
1. The series “Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Sanja Dacic served as the unpaid Guest Editor for the series.
